SCHEMBL5326834

SCHEMBL5326834

NS(=O)(=O)NCCCCCC(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 16/20 1.00
HDAC1 Q13547 13/20 0.70
HDAC2 Q92769 12/20 0.70
HDAC3 O15379 11/20 0.70
HDAC10 Q969S8 11/20 0.70
HDAC8 Q9BY41 11/20 0.70
HDAC4 P56524 10/20 0.70
HDAC7 Q8WUI4 10/20 0.70
HDAC11 Q96DB2 10/20 0.70
HDAC9 Q9UKV0 10/20 0.70
HDAC5 Q9UQL6 10/20 0.70
USP2 O75604 1/20 0.57
ALDH1A1 P00352 1/20 0.57
MAPT P10636 1/20 0.57
PKM P14618 1/20 0.57
ALOX15 P16050 1/20 0.57
MAPK1 P28482 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324571 0.84 HDAC1 (0.80) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL24359340 0.84 HDAC1 (0.80) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL24359677 0.83 HDAC1 (0.78) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL5328254 0.83 HDAC6 (0.81) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL24359341 0.82 HDAC1 (0.77) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL5481676 0.82 HDAC6 (1.00) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL5481686 0.82 HDAC6 (1.00) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL30444296 0.82 HDAC1 (0.80) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL35210420 0.82 HDAC1 (1.00) HDAC6HDAC1HDAC2HDAC3HDAC10
SCHEMBL11479812 0.82 HDAC1 (0.80) HDAC6HDAC1HDAC2HDAC3HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007143822-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-21 WO disclosed
WO-2007143822-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-21 WO disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 HDAC6 11/4885HDAC1 1/4885HDAC2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.